Protocol Ledger

NCT07384208 · Phase III · COMPLETED

A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5% in Patients With Acne Vulgaris (GEDACNE 2)

Interventional Phase III clinical trial protocol NCT07384208 sponsored by PPM Services in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-19 Enrollment: 398 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07384208
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)398 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07384208
Protocol FieldVerified Registry Value
NCT IdentifierNCT07384208
Consolidated Lead SponsorPPM Services
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment398 participants (ACTUAL)
Registered Start Date2024-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07384208
Hospital Research SiteLocationSite Profile
Azienda Ospedaliera Di PadovaPadova, ItalyOpen Hospital Dossier ->
Centrum Badan Klinicznych PI-House sp. z o.o.Gdansk, PolandOpen Hospital Dossier ->
Uniwersyteckie Centrum KliniczneGdansk, PolandOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI